The Bronchitis drugs in development market research report provides comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bronchitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bronchitis and features dormant and discontinued products.
GlobalData tracks 28 drugs in development for Bronchitis by 27 companies/universities/institutes. The top development phase for Bronchitis is preclinical with nine drugs in that stage. The Bronchitis pipeline has 28 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Bronchitis pipeline products market are: F. Hoffmann-La Roche, AstraZeneca and Icure Pharmaceutical.
The key targets in the Bronchitis pipeline products market include Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1), Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1), and Interleukin 1 Receptor Type 2 (CD121 Antigen Like Family Member B or CDw121b or IL 1 Type II Receptor or Interleukin 1 Receptor Beta or CD121b or IL1R2).
The key mechanisms of action in the Bronchitis pipeline product include Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1) Agonist with two drugs in Phase III. The Bronchitis pipeline products include nine routes of administration with the top ROA being Inhalational and five key molecule types in the Bronchitis pipeline products market including Small Molecule, and Recombinant Protein.
Bronchitis overview
Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked; shortness of breath aggravated by exertion or mild activity; frequent respiratory infections worsen symptoms; wheezing, fatigue, and headaches. Risk factors include smoking, older age and gastric reflux.
For a complete picture of Bronchitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
